BMO Capital Upgrades Gilead Sciences (GILD) to Outperform, 'Best-in-Class Cell Tx Biz'
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman upgraded Gilead Sciences (NASDAQ: GILD) from Market Perform to Outperform with a price target ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
